Ospedale S G Moscati
- Address
- lock Available on a paid plan
Ospedale S G Moscati - Comprehensive Oncology Research Center
Ospedale S G Moscati is a distinguished medical research institution with extensive expertise in hematologic malignancies and solid tumor oncology. The center demonstrates particular strength in investigating novel therapeutic combinations and biomarker-driven treatment strategies across multiple cancer types, with a focus on precision medicine approaches that optimize patient outcomes through personalized treatment selection.
- Acute Myeloid Leukemia (AML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia, including studies on minimal residual disease and chemo-free treatment strategies
- Colorectal cancer research emphasizing RAS/BRAF biomarker-driven therapies, liquid biopsy applications, and targeted immunotherapy combinations
- Thoracic oncology including non-small cell lung cancer (NSCLC), small-cell lung cancer, and malignant pleural mesothelioma
- Gynecologic oncology focusing on ovarian cancer with PARP inhibitor maintenance strategies and BRCA mutation studies
The center's clinical trial portfolio spans multiple therapeutic approaches including immunotherapy combinations, targeted molecular therapies, and innovative treatment sequencing strategies. Notable research includes studies combining checkpoint inhibitors with anti-EGFR therapies, novel antibody-drug conjugates in hematologic malignancies, and neoadjuvant strategies incorporating metabolic modulators. The institution also maintains an active respiratory medicine program investigating treatments for chronic obstructive pulmonary disease (COPD), demonstrating its commitment to comprehensive patient care beyond oncology.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 6 therapeutic areas and 15 of 64 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 64 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ospedale S G Moscati
lock Showing 1 of 21 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO). | AstraZeneca AB | Phase II | Recruiting | Sep 2025 | — |
IMP list
lock Showing 1 of 64 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bevacizumab | 6 | Unknown | 2020-01-31 | 2026-03-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.